Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Thyroid cancer
Trial Type:  Treatment
Results 1-25 of 28 for your search:
Start Over
Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D1532C00065, NCI-2013-01983, EudraCT 2013-000423-14, NCT01843062
Crolibulin and Cisplatin in Treating Patients with Recurrent or Metastatic Solid Tumors That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 90
Trial IDs: 11-C-0027, NCI-2013-01471, 110027, 343865, P10677, NCT01240590
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Genetically Modified Lymphocytes in Treating Patients with Thyroglobulin-Expressing Thyroid Cancer That Is Recurrent or Metastatic and Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 15-C-0090, NCI-2015-00499, 1412-1366, 150090, 342570, 8340274, P141702, RD14-XII-05, NCT02390739
A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PLX120-03, NCI-2015-00720, NCT02428712
Intensity-Modulated Radiation Therapy and Paclitaxel with or without Pazopanib Hydrochloride in Treating Patients with Anaplastic Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 0912, NCI-2011-02614, CDR0000688092, NCT01236547
Pasireotide and Everolimus in Treating Patients with Thyroid Cancer Refractory to Radioiodine
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: WCI1777-09, NCI-2011-03377, IRB00041909, NCT01270321
Pioglitazone Hydrochloride in Treating Patients with Thyroid Cancer
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: UMCC 2011.097, NCI-2012-01918, 2011.097, HUM00049615, NCT01655719
Biomarkers in Predicting Response in Patients with Locally Advanced Thyroid Cancer Receiving Vemurafenib before Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2012-0471, NCI-2012-02171, 00000363, NCT01709292
Dabrafenib with or without Trametinib in Treating Patients with Recurrent Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 12064, NCI-2012-01700, 2012C0074, NCCNGSK20008, NCT01723202
Cabozantinib-S-Malate in Treating Patients with Refractory Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 12154, NCI-2013-00554, 2012C0101, RU241210I, 9312, NCT01811212
Ponatinib Hydrochloride in Treating Patients with Localized or Metastatic Thyroid Cancer That Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-C-0108, NCI-2013-01589, 130108, 343948, P121010, NCT01838642
Pazopanib Hydrochloride in Treating Patients with Progressive Carcinoid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A021202, NCI-2013-00831, ALLIANCE A021202, CALGB-A021202, NCT01841736
Vaccine Therapy in Treating Patients with Recurrent or Metastatic Medullary Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-C-0095, NCI-2013-01587, GI-6207, GI-6207-02, P11934, NCT01856920
Intensity-Modulated Radiation Therapy in Treating Patients with Thyroid Cancer That is Recurrent or Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-070, NCI-2013-01187, NCT01882816
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 117019, NCI-2014-00802, NCT02034110
Thyroid Gland Removal With or Without Central Lymph Node Dissection in Treating Patients With Node Negative Thyroid Cancer
Phase: Phase II
Type: Treatment
Age: 21 to 70
Trial IDs: UW13115, NCI-2014-00833, 2014-0391, 2014-0391-CP002, NCT02138214
Sorafenib Tosylate with or without Everolimus in Treating Patients with Advanced, Radioactive Iodine Refractory Thyroid Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: A091302, NCI-2014-00623, NCT02143726
Inolitazone Dihydrochloride With or Without Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: A091305, NCI-2014-00686, NCT02152137
Trametinib in Increasing Tumoral Iodine Incorporation in Patients with Recurrent or Metastatic Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-157, NCI-2014-01106, 9446, NCT02152995
Iodine I-131 with or without Selumetinib in Treating Patients with Recurrent or Metastatic Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RU241306I, NCI-2015-00277, Mod14-008494-03, NCT02393690
Dabrafenib and Lapatinib Ditosylate in Treating Patients with Refractory Thyroid Cancer That Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-061, NCI-2013-01748, 9354, NCT01947023
Dabrafenib and Radioactive Iodine in Treating Patients With Papillary Thyroid Carcinoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-337, NCI-2012-00817, NCT01534897
Implanted Fiducial Markers in Assessing Treatment Accuracy and Esophageal Toxicity in Patients with Solid Tumors Undergoing Spinal Stereotactic Radiosurgery
Phase: No phase specified
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2012-0190, NCI-2012-01244, NCT01624220
Vemurafenib and Iodine I 131 in Treating Patients with BRAF Mutant, Radioiodine-Refractory Thyroid Cancer
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 14-031, NCI-2014-01210, NCT02145143
Start Over